2. Search Result
Search Result
Isoforms Recommended: CYP2
Results for "

CYP2C8

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

2

Natural
Products

11

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135335
    3'-Hydroxy Repaglinide

    		Drug Metabolite Metabolic Disease
    3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Repaglinide. Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes .
    3'-Hydroxy Repaglinide
  • HY-100641
    4-Hydroxytolbutamide

    Hydroxytolbutamide

    		 Potassium Channel Autophagy Metabolic Disease Cancer
    4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic .
    4-Hydroxytolbutamide
  • HY-N0319
    Salvianolic acid C
    3 Publications Verification

    		 Cytochrome P450 Cancer
    Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.
    Salvianolic acid C
  • HY-163438
    BKIDC-1553

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research .
    BKIDC-1553
  • HY-RS03459
    CYP2C8 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CYP2C8 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP2C8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP2C8 Human Pre-designed siRNA Set A
    CYP2C8 Human Pre-designed siRNA Set A
  • HY-E70471
    Human CYP2C8,High-Reductase

    		Cytochrome P450 Metabolic Disease
    Human CYP2C8, High-Reductase, a recombinant CYP2C8, is a member of the CYP enzyme family and is involved in the metabolism of xenobiotics in the body .
    Human CYP2C8,High-Reductase
  • HY-E70492
    Human CYP2C8,Low-Reductase

    		Cytochrome P450 Metabolic Disease
    Human CYP2C8, Low-Reductase, a recombinant CYP2C8, is a member of the CYP enzyme family and is involved in the metabolism of xenobiotics in the body .
    Human CYP2C8,Low-Reductase
  • HY-E70494
    Human CYP2C8,High-Reductase+b5

    		Cytochrome P450 Metabolic Disease
    Human CYP2C8, High-Reductase+b5, a recombinant CYP2C8, is a member of the CYP enzyme family and is involved in the metabolism of xenobiotics in the body .
    Human CYP2C8,High-Reductase+b5
  • HY-E70495
    Human CYP2C8,Low-Reductase+b5

    		Cytochrome P450 Metabolic Disease
    Human CYP2C8, ,Low-Reductase+b5, a recombinant CYP2C8, is a member of the CYP enzyme family and is involved in the metabolism of xenobiotics in the body .
    Human CYP2C8,Low-Reductase+b5
  • HY-124542
    5-Hydroxydiclofenac

    		Drug Metabolite Apoptosis Cancer
    5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .
    5-Hydroxydiclofenac
  • HY-N0319R
    Salvianolic acid C (Standard)

    		Cytochrome P450 Cancer
    Salvianolic acid C (Standard) is the analytical standard of Salvianolic acid C. This product is intended for research and analytical applications. Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.
    Salvianolic acid C (Standard)
  • HY-135810
    Cletoquine

    Desethylhydroxychloroquine

    		 Influenza Virus Parasite Infection Inflammation/Immunology
    Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment .
    Cletoquine
  • HY-135331
    N-Desmethyl-Apalutamide

    		Androgen Receptor Cytochrome P450 Cancer
    N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .
    N-Desmethyl-Apalutamide
  • HY-135335S
    3'-Hydroxy Repaglinide-d5

    		Drug Metabolite Metabolic Disease
    3'-Hydroxy Repaglinide-d5 is the deuterium labeled 3'-Hydroxy Repaglinide. 3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Repaglinide[1].
    3'-Hydroxy Repaglinide-d5
  • HY-135810A
    Cletoquine oxalate

    Desethylhydroxychloroquine oxalate

    		 Influenza Virus Parasite Infection Inflammation/Immunology
    Cletoquine oxalate (Desethylhydroxychloroquine oxalate) is a major active metabolite of Hydroxychloroquine. Cletoquine oxalate is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine oxalate is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine oxalate has antimalarial effects and has the potential for autoimmune diseases treatment .
    Cletoquine oxalate
  • HY-155376
    mTOR inhibitor-14

    		mTOR Cancer
    mTOR inhibitor-14 (compound 14c) is a potent mTOR inhibitor. mTOR inhibitor-14 also shows minimal CYP2C8 inhibition. mTOR inhibitor-14 can inhibit tumor growth .
    mTOR inhibitor-14
  • HY-129993
    Gemfibrozil 1-O-β-glucuronide

    		PPAR Cytochrome P450 Drug Metabolite Cardiovascular Disease Metabolic Disease
    Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive P450 (CYP) isoform CYP2C8 inhibitor with an IC50 of 4.07 μM .
    Gemfibrozil 1-O-β-glucuronide
  • HY-119311
    Ketopioglitazone

    		PPAR Metabolic Disease
    Pioglitazone ketone is an active metabolite of the PPARγ agonist Pioglitazone (HY-13956). Formation of pioglitazone ketone occurs primarly through cytochrome P450 (CYP) isoform CYP2C8-mediated metabolism of pioglitazone. Pioglitazone ketone (100 mg/kg in the diet) reduces blood glucose levels in a KKAy mouse model of type 2 diabetes.
    Ketopioglitazone
  • HY-W754151
    N-Desmethyl apalutamide-d4

    		Isotope-Labeled Compounds Others
    N-Desmethyl apalutamide-d4 is the deuterium-labeled N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .
    N-Desmethyl apalutamide-d4
  • HY-100641S
    4-Hydroxytolbutamide-d9

    Hydroxytolbutamide-d9

    		 Potassium Channel Autophagy Metabolic Disease Cancer
    4-Hydroxytolbutamide-d9 is the deuterium labeled 4-Hydroxytolbutamide. 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic[1][2].
    4-Hydroxytolbutamide-d9
  • HY-135334
    ACP-5862
    1 Publications Verification

    		 Drug Metabolite Btk Cytochrome P450 Cancer
    ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM .
    ACP-5862
  • HY-17356
    Fenofibrate
    Maximum Cited Publications
    17 Publications Verification

    		 PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate
  • HY-114759
    MS-PPOH

    		Cytochrome P450 Neurological Disease Metabolic Disease Cancer
    MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC50s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MS-PPOH
  • HY-135810S
    Cletoquine-d4

    Desethylhydroxychloroquine-d4

    		 Isotope-Labeled Compounds Influenza Virus Parasite Infection Inflammation/Immunology
    Cletoquine-d4 is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].
    Cletoquine-d4
  • HY-135810S1
    Cletoquine-d4-1

    Desethylhydroxychloroquine-d4-1

    		 Isotope-Labeled Compounds Influenza Virus Parasite Infection Inflammation/Immunology
    Cletoquine-d4-1 is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].
    Cletoquine-d4-1
  • HY-17356S
    Fenofibrate-d6

    		Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-d6
  • HY-135334S
    ACP-5862-d4

    		Isotope-Labeled Compounds Drug Metabolite Btk Cytochrome P450 Cancer
    ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].
    ACP-5862-d4
  • HY-17356S1
    Fenofibrate-d4

    		PPAR Autophagy Cytochrome P450 Cardiovascular Disease
    Fenofibrate-d4 is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].
    Fenofibrate-d4
  • HY-17356R
    Fenofibrate (Standard)
    Maximum Cited Publications
    17 Publications Verification

    		 PPAR Cytochrome P450 Autophagy Cardiovascular Disease Cancer
    Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate (Standard)
  • HY-17356S2
    Fenofibrate-13C6

    		Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy Cardiovascular Disease
    Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate-13C6
  • HY-116862
    Dibenzylfluorescein

    DBF

    		 Cytochrome P450 Fluorescent Dye Others
    Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its Km value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .
    Dibenzylfluorescein
  • HY-17356G
    Fenofibrate

    		Cytochrome P450 PPAR Autophagy Cardiovascular Disease
    Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate
  • HY-117160
    4-trans-Hydroxy-glibenclamide

    4-trans-hydroxycyclohexyl Glyburide; 4-trans-hydroxy Glibenclamide

    		 Potassium Channel Neurological Disease
    rac-trans-4-hydroxy Glyburide is an active metabolite of the SUR1/Kir6.2 sulfonylurea inhibitor glyburide (HY-15206). It is formed from glyburide by the cytochrome P450 (CYP) isoforms CYP2C8 and CYP2C9. rac-trans-4-hydroxy Glyburide inhibits glyburide binding to rat brain synaptosomes at the high and low affinity sites of SUR1/Kir6.2 with IC50 values of 0.95 and 100 nM, respectively.
    4-trans-Hydroxy-glibenclamide
  • HY-W587878
    Thujopsene

    		Cytochrome P450 Pyruvate Kinase Fungal Apoptosis Insecticide Infection Cancer
    Thujopsene is the inhibitor for cytochrome P450, that inhibits CYP2B6, CYP3A4, CYP2C19, CYP2C8, CYP2C9 with IC50s of 1.3, 12.6, 13.6, 29.8, and 44.9 μM, respectively. Thujopsene binds to PKM2, inhibits the metabolism pathway of cancer cell, induces apoptosis in MKN45, thereby exhibiting antitumor efficacy. Thujopsene exhibits anti-termite and antifungal activities through autoxidation .
    Thujopsene
  • HY-135331S
    N-Desmethyl-Apalutamide-15N,d4

    		Isotope-Labeled Compounds Androgen Receptor Cytochrome P450 Cancer
    N-Desmethyl-Apalutamide-15N,d4 is the 15N and deuterium labeled isotope of N-Desmethyl-Apalutamide (HY-135331). N-Desmethyl Apalutamide is an active metabolite of Apalutamide. N-Desmethyl Apalutamide is a less potent antagonist of the androgen receptor and is responsible for one-third of the activity of Apalutamide. The formation of N-Desmethyl Apalutamide mediated predominantly by CYP2C8 and CYP3A4. N-Desmethyl Apalutamide is moderate to strong CYP3A4 and CYP2B6 inducer and has an excellent plasma-proteins bound concentration .
    N-Desmethyl-Apalutamide-15N,d4
  • HY-148352
    BAY-4931

    		PPAR Cancer
    BAY-4931 is a potent, covalent and selective PPARγ inverse-agonist with an IC50 of 0.17 nM .
    BAY-4931
  • HY-70002AS
    N-desmethyl Enzalutamide-d6

    N-desmethyl MDV 3100-d6

    		 Androgen Receptor Cancer
    N-desmethyl Enzalutamide-d6 is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1].
    N-desmethyl Enzalutamide-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: